Introduction: The Changing Narrative of FIGS Stock

For years, the direct-to-consumer (DTC) healthcare apparel brand FIGS, Inc. (NYSE: FIGS) was one of Wall Street's most polarizing stocks. After a spectacular initial public offering in 2021 that valued the company at over $4.5 billion, FIGS faced a challenging multi-year valuation reset. High inflation, rising freight costs, and concerns over the depth of the medical uniform market sent the share price tumbling from its pandemic-era highs.

However, as we move through mid-2026, the narrative surrounding figs stock has shifted. A blowout Q1 2026 earnings report, characterized by a 28% year-over-year revenue surge and an upgraded full-year outlook, has rekindled investor optimism. The company has officially surpassed the 3 million active customer milestone, proving that its de-commoditized approach to medical scrubs is far from a passing fad.

If you are evaluating figs stock today, you are likely asking: is this recent operational acceleration a temporary rebound, or is FIGS successfully transitioning from a niche brand into a global medical lifestyle powerhouse? This comprehensive guide breaks down the investment thesis, parses the latest financial metrics, highlights critical growth catalysts, and analyzes the competitive landscape to help you make an informed decision.

The Core Investment Thesis: Beyond Commoditized Scrubs

To understand the long-term potential of figs stock, one must first understand how the company revolutionized a stagnant, multi-billion-dollar industry. Traditionally, medical scrubs were treated as low-cost commodities. Healthcare workers purchased oversized, boxy, and uncomfortable uniforms from specialized medical-supply stores. Brand loyalty was virtually non-existent, and the purchasing experience was thoroughly uninspired.

De-Commoditizing a Stagnant Market

Co-founders Heather Hasson and Trina Spear realized that medical professionals spend 12 to 14 hours a day in these garments, yet had zero options that combined utility with athletic-style comfort and aesthetic appeal. FIGS de-commoditized scrubs by introducing premium fabrics, tailored fits, and high-performance functionality. By formulating its proprietary FIONx fabric—which boasts four-way stretch, moisture-wicking, anti-odor, and antimicrobial properties—FIGS created a product that felt more like activewear from premium brands than standard medical uniforms. It turned scrubs into a status symbol and a source of professional pride, building a highly passionate community of 'Awesome Humans'.

A High-Margin, Digitally Native DTC Engine

The business model of FIGS is predominantly direct-to-consumer (DTC), which accounts for roughly 98% of its revenue. By bypassing traditional wholesalers and brick-and-mortar intermediaries, FIGS retains incredible margin control. The company boasts industry-leading gross margins consistently hovering between 67% and 69%.

Moreover, FIGS drives consumer engagement through a 'drop model' similar to streetwear brands. Frequent, limited-edition colorways and product styles create a sense of urgency and excitement. This strategy has resulted in stellar customer lifetime value metrics. As of the first quarter of 2026, approximately 70% of FIGS' net revenues came from repeat purchases. This high customer retention rate significantly reduces its long-term customer acquisition costs (CAC) and creates a highly predictable, recurring revenue stream.

Furthermore, FIGS has built a powerful digital interface. Its proprietary mobile app has become the primary sales driver, facilitating over 60% of digital transactions and continuing to scale in 2026. The app allows FIGS to capture rich consumer data, optimize personalized merchandising, and communicate directly with its customer base, creating a defensive moat that traditional medical apparel manufacturers struggle to replicate.

Q1 2026 Financial Analysis: Back to Growth and Profitability

After a period of consolidation where growth slowed to the single digits, FIGS' recent earnings reports indicate that its strategic brand reset is paying off. Let's do a deep dive into the latest financial numbers from Q1 2026, which were released on May 7, 2026.

Key Financial Highlights

• Net Revenue: FIGS reported quarterly revenue of $159.9 million, representing a robust 28.0% increase year-over-year. This significantly beat Wall Street expectations of $152.48 million and outpaced management's original guidance, which projected growth in the low-20% range.
• Earnings Per Share (EPS): The company posted a diluted EPS of $0.03, representing a 200% positive surprise against the analyst consensus estimate of $0.01. This marks a major profitability inflection compared to the breakeven or slight net loss reported in the prior year's first quarter.
• Active Customers: The active customer base expanded by 12.2% year-over-year, officially surpassing 3.0 million active users for the first time.
• Average Order Value (AOV): AOV improved by 4.0% to $124, driven by strong adoption of premium product tiers and successful cross-selling of non-scrubwear items. Net revenue per active customer reached $220.
• Margins: Gross margin came in at 67.7%, reflecting a 10 basis point expansion year-over-year. This expansion is particularly impressive considering the company faced persistent tariff uncertainties and elevated inbound freight surcharges. Adjusted EBITDA grew to $13.9 million, translating to an Adjusted EBITDA margin of 8.7% (up from 7.3% in Q1 2025).

Segment Breakdown

FIGS' revenue acceleration was exceptionally balanced across its product lines and geographical markets:

• Scrubwear: Accounting for 79% of net revenues, the core scrubwear business grew by 27.2% to $126.6 million.
• Non-Scrubwear: Consisting of lifestyle outerwear, under-scrubs, activewear, footwear, and compression socks, this high-growth segment expanded by 31.3% to $33.3 million (now representing 21% of overall revenue).
• U.S. vs. International: While domestic U.S. revenue increased by a healthy 24.1% to $131.6 million, international revenues surged by 49.9% to $28.3 million, highlighting the massive global runway for the brand.

Raised Guidance and Balance Sheet Strength

Riding the momentum of this stellar start, management raised its full-year 2026 net revenue growth outlook to 14% to 16% (up from low-double digits previously expected). They also increased their full-year Adjusted EBITDA margin targets to a range of 13.0% to 13.2%.

Crucially for conservative investors, FIGS possesses an incredibly resilient, pristine balance sheet. The company has zero debt and maintains a robust cash reserve, giving it the flexibility to aggressively fund international expansion, invest in product innovation, and navigate macroeconomic volatility without the pressure of high interest rates.

Key Growth Catalysts: What Will Drive FIGS Stock Higher?

While the core scrubwear market remains highly profitable, FIGS is executing several structural initiatives to expand its total addressable market (TAM) and unlock multi-year growth channels.

1. Global Market Penetration

International expansion is currently the fastest-growing lever for FIGS. In Q1 2026, international sales surged by nearly 50%, fueled by aggressive localization and targeted marketing. FIGS is now active in over 85 international markets, with massive momentum building in Canada, Australia, the United Kingdom, and the Middle East, alongside highly anticipated rollouts in Japan and South Korea. Because the medical apparel market is highly fragmented globally, FIGS' unified lifestyle branding has allowed it to easily cross borders and capture early market share.

2. The B2B 'TEAMS' Platform

Historically, FIGS sold almost exclusively to individual healthcare professionals. However, hospitals, clinics, and academic institutions are increasingly looking to standardize uniform quality, colors, and branding across their departments. To address this corporate demand, FIGS launched its custom 'TEAMS' platform. By streamlining bulk B2B purchases, integrating digital team stores, and allowing custom embroidery, FIGS is successfully winning large institutional contracts. This institutional sales channel diversifies its revenue away from pure consumer discretionary spending, reduces churn, and provides highly reliable, bulk order volumes.

3. Non-Scrubwear and Lifestyle Cross-Selling

Healthcare professionals do not just need scrubs; they need athletic wear for their off-days, high-quality base layers for long shifts, supportive footwear, and specialized outerwear. By expanding into non-scrubwear (such as fleece jackets, hoodies, compression socks, and athletic shoes), FIGS is maximizing its wallet share among existing customers. This cross-selling strategy is highly capital-efficient, as it leverages FIGS' existing customer database without requiring incremental marketing acquisition costs.

4. Retail Footprint and 'Community Hubs'

Although FIGS is a digital-first company, offline retail is becoming a powerful brand anchor. The company is selectively rolling out physical stores, which it terms 'Community Hubs,' strategically located within five miles of major medical centers and teaching hospitals. These physical spaces serve a dual purpose. They allow healthcare professionals to touch, try on, and experience FIONx fabrics firsthand, and they act as physical gathering spaces for local medical communities. Management has noted that the unit economics of these 2,500 to 3,000-square-foot stores are exceeding all internal expectations, creating a powerful 'halo effect' that actively drives localized online e-commerce sales.

Competitive Moat vs. Rising Rivals: Can FIGS Maintain Its Lead?

To evaluate figs stock, we must examine the competitive landscape. The medical scrubs industry is fiercely competitive, but FIGS operates with a distinct advantage.

Traditional Competitors

The market historically belonged to legacy players like Careismatic Brands (the owner of Cherokee Uniforms, Dickies Medical, and Infinity) and Barco Uniforms (famous for its licensed Grey's Anatomy line). These companies generate substantial revenues but rely on traditional brick-and-mortar retail distribution and wholesale agreements. Because they sell through third parties, they have lower gross margins, slow feedback loops, and lack the digital-first customer relationship that FIGS dominates. Furthermore, legacy brands find it difficult to replicate FIGS' lifestyle appeal because their marketing engines are structured around business-to-business wholesaling rather than direct-to-consumer cultural influence.

Premium Boutique Entrants

The success of FIGS has naturally attracted boutique alternatives and direct-to-consumer copycats. Brands like Jaanuu, Poppy Scrubs, and Titan Scrubs have emerged, offering premium athletic fits and performance fabrics at various price points. While these brands compete directly for the premium consumer, FIGS' massive scale gives it significant advantages:

• Brand Equity: FIGS has established itself as the 'aspirational' standard. For many medical students and young professionals, buying a set of FIGS is a celebratory milestone.
• Marketing Scale: FIGS has the capital to invest in massive global marketing campaigns. For example, its high-profile sponsorship of medical staff at the Olympic Games elevates the brand to a global stage in a way that smaller boutique players simply cannot afford.
• Sourcing and Margins: FIGS' scale allows it to secure tier-one manufacturing partnerships across Vietnam and other global hubs, ensuring highly competitive production costs and maintaining gross margins near 68%, whereas smaller competitors must accept thinner margins to compete on price.

Valuation and Price Targets: Is FIGS Stock a Buy, Sell, or Hold?

With FIGS' shares trading in the $11.50 to $12.50 range as of mid-2026, the market is actively trying to determine the stock's fair value.

The Bull Case

Wall Street analysts have become increasingly bullish on figs stock following the Q1 2026 operational turnaround. According to consensus data compiled from S&P Global, the average 1-year price target for FIGS stands at $17.63, representing a potential upside of over 40% from current trading levels. Key investment firms have issued aggressive price targets:

• BTIG maintains a 'Strong Buy' rating with a price target of $20.00.
• KeyBanc recently raised its price target to $19.00, citing robust DTC metrics and strong e-commerce engagement.
• Oppenheimer upgraded the stock to a 'Buy' with a price target of $22.00, highlighting the accelerating B2B TEAMS platform and international expansion.

Proponents of the bull case argue that a company growing at 28% year-over-year, carrying zero debt, and maintaining 67%+ gross margins is heavily undervalued when trading at a market capitalization of around $2 billion.

The Bear Case / Conservative View

Conversely, more conservative value investors urge caution, pointing to valuation multiples. At current prices, FIGS trades at roughly 30x forward Adjusted EBITDA. Independent financial analytics platforms, such as Simply Wall St, argue that based on conservative long-term discounted cash flow (DCF) models, a fair value closer to $7.21 might be more appropriate if the company's margin progress stalls. Skeptics note that the brand's premium pricing makes it sensitive to macroeconomic downturns. If hospital staff budgets shrink or inflation continues to squeeze consumer discretionary income, medical professionals may opt for cheaper alternative brands or delay their purchasing cycles.

Additionally, marketing expenses remain high. In Q1 2026, marketing spend sat at 18.4% of revenue due to aggressive campaigns like the Winter Olympics. If FIGS must continuously spend heavily on marketing to maintain its 28% growth rate, long-term operating margin expansion may be capped.

Critical Risks and Downside Factors to Watch

No investment is without risk. If you are holding or considering buying figs stock, keep a close eye on these potential headwinds:

• Tariff and Trade Policies: FIGS sources a significant portion of its products from international manufacturers, primarily in Vietnam. Any sudden shifts in global tariff structures could put immediate pressure on gross margins. Although FIGS has locked in its pricing through the end of 2026, future tariff changes remain a key variable.
• Inbound Freight and Oil Prices: Because FIGS' products are polyester-based and shipped globally, rising oil prices and maritime freight surcharges can impact cost of goods sold (COGS). While management has successfully mitigated this through operational efficiency, persistent shipping bottlenecks present a risk.
• Geopolitical Pressures: Some regional conflicts have caused localized headwinds. For instance, in Q1 2026, management noted that growth in the Middle East was sequentially slower due to ongoing regional tensions.
• Core Market Saturation: While the U.S. healthcare apparel market is large, the premium segment is not infinite. FIGS must continue to successfully execute its international and non-scrubwear expansion to avoid hitting a growth ceiling domestically.

Frequently Asked Questions (FAQs)

Is FIGS stock a good long-term investment?

FIGS exhibits strong fundamentals, including a debt-free balance sheet, premium gross margins (67%+), and a highly loyal customer base with a 70% repeat purchase rate. Its recent Q1 2026 revenue acceleration of 28% suggests that its growth catalysts are actively materializing. For growth-oriented investors, the stock presents an attractive risk-reward profile, though it is subject to short-term market volatility and macro-driven discretionary spending risks.

Why did FIGS stock fall after beating its earnings forecasts?

Despite beating both revenue and earnings estimates in Q1 2026, FIGS stock experienced short-term volatility post-earnings. This is common in high-growth consumer stocks, where profit-taking, concerns over elevated marketing spend (18.4% of revenue in Q1), and broader macroeconomic anxieties regarding tariffs and freight costs often cause temporary price consolidation.

Who is FIGS' biggest competitor?

FIGS' traditional competitors are legacy medical uniform giants, primarily Careismatic Brands (Cherokee, Dickies) and Barco Uniforms (Grey's Anatomy). In the premium direct-to-consumer space, emerging competitors include Jaanuu, Poppy Scrubs, and Titan Scrubs.

What are the main growth drivers for FIGS?

The key drivers pushing FIGS' long-term growth are aggressive international market penetration (now in 85 markets), the expansion of its corporate B2B 'TEAMS' store, the cross-selling of its rapidly growing non-scrubwear lifestyle catalog, and the rollout of physical 'Community Hub' retail stores.

Conclusion: Weighing the Upside of FIGS Stock

FIGS, Inc. has successfully proven that its business model is more than a short-term trend. By de-commoditizing healthcare uniforms and capturing the ultimate mindshare of over 3 million active medical professionals, the company has established a formidable niche.

With its recent financial turnaround in Q1 2026—delivering a massive 28% revenue beat, raising full-year outlooks, and maintaining a debt-free balance sheet—the operational story is incredibly healthy. While valuation multiples around 30x forward EBITDA and near-term tariff risks require careful monitoring, the long-term runway for international, B2B, and offline retail expansion makes figs stock a highly compelling growth prospect for patient investors looking to capitalize on the modernization of healthcare apparel.